As a rare disease, cystic fibrosis (CF) didn’t get much attention from the pharmaceutical industry, and as a result the outlook for patients was bleak—a lifetime of lung infections and a life expectancy that rarely extended beyond the mid-30s. That’s all changing now, as more than a half-dozen pharmaceutical and biotech companies have entered the race to develop better treatments, and even cures for CF.
This ebook will examine the changing landscape in CF, with input from drug developers, patients, and physicians. It will look at the science behind the newest remedies for this disease, including ongoing efforts to identify and target genetic mutations that contribute to CF. And it will analyze the commercialization strategies companies are employing to make the most of this market—which is projected to grow from $695.6 million in sales in 2012 to almost $4.5 billion in 2019.
Major research programs underway at pharmaceutical giants such as Novartis and Pfizer, the latter of which is working with a $58 million research grant from the CF Foundation
The race among smaller companies such as AbbVie, Insmed, and Kala Pharma to develop next-generation treatments
The impact of a highly publicized but faulty rollout of Vertex Pharmaceuticals’ new CF drug
IPLEX =In March 2013, we amended the Premacure License Agreement to provide Premacure with the option to pay us $11.5 million and assume any of our royalty obligations to other parties in exchange for a fully paid license. In March 2013, Shire plc announced that they acquired Premacure. In April 2013 Shire exercised this option and paid us $11.5 million, and as a result we are not entitled to future royalties from Shire